metastatic/advanced OC (mOC) - 1st line (L1) | |
metastatic/advanced OC (mOC) - 1st line (L1) | |
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | AGO-OVAR 2.29/ENGOT-ov34 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -